KImedi GmbH, a start-up company, supports doctors in finding diagnoses by applying digital technologies of artificial intelligence (AI) and machine learning as well as the combination of human experience and medical knowledge. Based on a mathematical analysis of patient data obtained from patient surveys, KImedi’s AI algorithms know a variety of diseases, do not forget medical knowledge and shorten the path to diagnosis, especially for patients with rare diseases.
In this project ARTIS, KImedi would now like to make the developed systems in the field of neuromuscular diseases, including Pompe’s disease, accessible to a broad public and encourage their use. This broad application, involving cooperating physicians and medical centres, is intended to support the diagnostic process, while at the same time providing information to further improve it through new input for the AI algorithms.
KImedi GmbH is supported both financially and logistically by SANOFI GENZYME. SANOFI GENZYME belongs to the Sanofi-Aventis Germany GmbH and is a biotechnology company specializing in the development, production, marketing and distribution of pharmaceuticals.
Interested physicians and medical centres are invited to participate in the project free of charge, thereby adding another high-tech instrument to their diagnostic tools.
The project will start in autumn 2020.